共 50 条
Biological quality control for cardiopulmonary exercise testing in multicenter clinical trials
被引:8
|作者:
Porszasz, Janos
[1
]
Blonshine, Susan
[2
]
Cao, Robert
[1
]
Paden, Heather A.
[3
]
Casaburi, Richard
[1
]
Rossiter, Harry B.
[1
,4
]
机构:
[1] Harbor UCLA Med Ctr, Los Angeles Biomed Res Inst, Rehabil Clin Trials Ctr, 1124W Carson St,Bldg CDCRC, Torrance, CA 90502 USA
[2] TechEd Consultants Inc, Mason, MI USA
[3] Boehringer Ingelheim Pharmaceut Inc, 90 E Ridge POB 368, Ridgefield, CT 06877 USA
[4] Univ Leeds, Fac Biol Sci, Leeds, W Yorkshire, England
来源:
关键词:
Calibration;
Treadmill test;
Pulmonary gas exchange;
Z-score;
Precision and accuracy;
OBSTRUCTIVE PULMONARY-DISEASE;
PEDALING RATES;
TOLERANCE;
COPD;
RECOMMENDATIONS;
HYPERINFLATION;
TIOTROPIUM;
ASSURANCE;
BENEFITS;
OXYGEN;
D O I:
10.1186/s12890-016-0174-8
中图分类号:
R56 [呼吸系及胸部疾病];
学科分类号:
摘要:
Background: Precision and accuracy assurance in cardiopulmonary exercise testing (CPET) facilitates multicenter clinical trials by maximizing statistical power and minimizing participant risk. Current guidelines recommend quality control that is largely based on precision at individual testing centers (minimizing test-retest variability). The aim of this study was to establish a multicenter biological quality control (BioQC) method that considers both precision and accuracy in CPET. Methods: BioQC testing was 6-min treadmill walking at 20 W and 70 W (below the lactate threshold) with healthy non-smoking laboratory staff (15 centers; similar to 16 months). Measurements were made twice within the initial 4 weeks and quarterly thereafter. Quality control was based on: 1) within-center precision (coefficient of variation [CV] for oxygen uptake [(V) over dotO(2)], carbon dioxide output [(V) over dotCO(2)], and minute ventilation [(V) over dotE] within +/- 10 %); and 2) a criterion that (V) over dotO(2) at 20 W and 70 W, and Delta(V) over dotO(2)/Delta WR were each within +/- 10 % predicted. "Failed" BioQC tests (i.e., those outside the predetermined criterion) prompted troubleshooting and repeated measurements. An additional retrospective analysis, using a composite z-score combining both BioQC precision and accuracy of (V) over dotO(2) at 70 W and Delta(V) over dotO(2)/Delta WR, was compared with the other methods. Results: Of 129 tests (5 to 8 per center), 98 (76 %) were accepted by within-center precision alone. Within-center CV was <9 %, but between-center CV remained high (9.6 to 12.5 %). Only 43 (33 %) tests had all (V) over dotO(2) measurements within the +/- 10 % predicted criterion. However, a composite z-score of 0.67 identified 67 (52 %) non-normal outlying tests, exclusion of which coincided with the minimum CV for CPET variables. Conclusions: Study-wide BioQC using a composite z-score can increase study-wide precision and accuracy, and optimize the design and conduct of multicenter clinical trials involving CPET.
引用
收藏
页数:10
相关论文